New cocktail of drugs shows promise for Hard-to-Treat prostate cancer
NCT ID NCT03431350
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This phase 2 trial is testing several drug combinations—including niraparib, cetrelimab, abiraterone acetate, and prednisone—in 136 men with metastatic castration-resistant prostate cancer (mCRPC), a form of the disease that has spread and stopped responding to standard hormone therapy. The study aims to find the safest and most effective doses and to measure how well the combinations shrink tumors or lower cancer markers. While the results could lead to better treatment options, the trial is still early and the side effects can be serious.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- niraparib, cetrelimab, abiraterone acetate, prednisone
- What this could lead to
- If successful, this could point toward new combination treatments that slow or shrink advanced prostate cancer that has stopped responding to standard hormone therapy.
- What could go wrong
- This is a mid-stage trial with only 136 participants, so results may not apply to all patients. The drug combinations can cause serious side effects, and it is not yet known if they work better than existing options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST Grande Ospedale Metropolitano Niguarda
Milan, 20162, Italy
-
Asaf Harofe Medical Center
Beer Yaakov, 60930, Israel
-
Az Groeninge
Kortrijk, 8500, Belgium
-
Azienda Ospedaliera ''Vito Fazzi''
Lecce, 73100, Italy
-
Azienda Ospedaliera Universitaria Careggi di Firenze
Florence, 50134, Italy
-
British Columbia Cancer Agency
Vancouver, British Columbia, V5Z4E6, Canada
-
Carolina Urologic Research Center
Myrtle Beach, South Carolina, 29572, United States
-
Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
Liège, B-4000, Belgium
-
Centre de Recherche du CHUM
Montreal, Quebec, H2X 0A9, Canada
-
Chesapeake Urology Research Associates
Towson, Maryland, 21204, United States
-
First Urology, PSC
Jeffersonville, Indiana, 47130, United States
-
Hosp Univ Fund Jimenez Diaz
Madrid, 28040, Spain
-
Hosp Univ Hm Sanchinarro
Madrid, 28050, Spain
-
Hosp Virgen de La Victoria
Málaga, 29010, Spain
-
Hosp. Univ. de La Princesa
Madrid, 28006, Spain
-
Hosp. de La Santa Creu I Sant Pau
Barcelona, 08025, Spain
-
Hospital Vall D'Hebron
Barcelona, 8035, Spain
-
Houston Metro Urology
Houston, Texas, 77027, United States
-
IRCCS-Fondazione Pascale
Naples, 80131, Italy
-
MUSC-Hollings Cancer Center
Charleston, South Carolina, 29425, United States
-
Mayo Clinic - Division Of Hematology/oncology
Jacksonville, Florida, 32224, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center 1
Harrison, New York, 10604, United States
-
Michigan Institute of Urology
Troy, Michigan, 48084, United States
-
New York Oncology Hematology
Albany, New York, 12208, United States
-
OLV Ziekenhuis Aalst
Aalst, 9300, Belgium
-
Princess Margaret Cancer Centre University Health Network
Toronto, Ontario, M5G2M9, Canada
-
Rabin Medical Center
Petah Tikva, 49100, Israel
-
Rambam Medical Center
Haifa, 31096, Israel
-
Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital
Truro, TR1 3LJ, United Kingdom
-
Royal United Hospital
Bath, BA1 3NG, United Kingdom
-
Sheba Medical Center Tel Hashomer
Ramat Gan, 52621, Israel
-
Soroka Hospital
Beersheba, 85101, Israel
-
Southampton General Hospital
Southampton, SO16 6YD, United Kingdom
-
Southern Alberta Institute of Urology / Prostate Cancer Centre
Calgary, Alberta, T2V 1P9, Canada
-
The Royal Marsden NHS Trust Sutton
Sutton, SM2 5PT, United Kingdom
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
The Urology Center of Colorado
Denver, Colorado, 80211, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
ULB Hôpital Erasme
Brussels, 1070, Belgium
-
UOC Oncologia Ospedale Provinciale di Macerata
Province of Macerata, 62100, Italy
-
Universitair Ziekenhuis Gent
Ghent, 9000, Belgium
-
University College London Hospitals
London, WC1E 6BT, United Kingdom
-
University of Pittsburgh Medical Center (UPMC)
Pittsburgh, Pennsylvania, 15232, United States
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 5379200, United States
-
Urological Associates of Southern Arizona, P.C.
Tucson, Arizona, 85741, United States
-
Urology Associates
Nashville, Tennessee, 37209, United States
-
Urology of Virginia, PLCC
Virginia Beach, Virginia, 23462, United States
-
Utah Cancer Specialists
Salt Lake City, Utah, 84106, United States
-
ZNA Middelheim
Antwerp, 2020, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blast of testosterone shrink hard-to-treat prostate cancer?
- Can a Two-Drug attack stall resistant prostate cancer?
- A PET scan and a blood test may predict which men with advanced prostate cancer will benefit from targeted therapy
- Can a new daily pill slow advanced prostate cancer?
- Radiation plus hormone therapy may slow resistant prostate cancer
- Targeted radiation zaps prostate cancer cells in new trial